| Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|---|
| Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio | ||||||||
| NX-2127 | BTK + IMiD Activity (Oral) | B-cell malignancies |
| |||||
| NX-5948 | BTK (Oral) | B-cell malignancies and autoimmune disease |
| |||||
| KINASE-CTM3 | Undisclosed | T-cell malignancies and autoimmune disease |
| |||||
| COVID-CTMs | 3 targets | Anti-viral |
| |||||
| Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Ligase Inhibitor Portfolio | ||||||||
| NX-1607 | CBL-B (Oral) | Immuno-oncology |
| |||||
| DeTIL-0255 | CBL-B (ex vivo) | Tumor infiltrating lymphocytes |
| |||||
| LIGASE-INH2 | Undisclosed | Immuno-oncology |
| |||||
| Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Partners and Subsidiaries | ||||||||
| DeCART | CBL-B and others (ex vivo) | Chimeric antigen receptor T‑cells (CAR-T) |
| |||||
| Gilead Sciences | 5 targets | Undisclosed | Undisclosed Progress
| |||||
| Sanofi | 5 targets | Undisclosed | Undisclosed Progress
| |||||
| Candidate / Target | Phase |
|---|---|
| Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio | NX-2127 BTK + IMiD Activity (Oral) | Phase 1 |
| NX-5948 BTK (Oral) | Preclinical |
| KINASE-CTM3 Undisclosed | Lead Optimization |
| COVID-CTMs 3 targets | Discovery |
| Ligase Inhibitor Portfolio | NX-1607 CBL-B (Oral) | Preclinical |
| DeTIL-0255 CBL-B (ex vivo) | Preclinical |
| LIGASE-INH2 Undisclosed | Lead Optimization |
| Partners and Subsidiaries | DeCART CBL-B and others (ex vivo) | Lead Optimization |
| Gilead Sciences 5 targets | Undisclosed Progress |
| Sanofi 5 targets | Undisclosed Progress |
'